Biomarkers Clinical Trial
Official title:
Usefulness of Cell-free DNA Quantification With Fluorescent Assay in Response Evaluation of Palliative Chemotherapy
This study is design to address, as follows: 1. correlation between fluorescence-based CFD measurements and tumor burden (primary tumor size, number of metastatic sites) 2. fluorescence-based CFD measurements and changes are related to tumor response. Based on the results of this study, the role of fluorescence-based CFD as a predictive biomarker for palliative chemotherapy is to be confirmed.
- It is important to check the response to chemotherapy. Currently, it is mostly evaluated as a radiologic response or, rarely the change of tumor markers. - In the case of radiologic response tests at intervals of 6-8 weeks, there are cases where the economic burden and radiation exposure risk, additionally evaluation lesion is lack in a few case. Except for prostate cancer and ovarian cancer, the majority of carcinomas do not have cancer markers for assessing treatment response. Therefore, there is a need for biomarkers that can predict the response of anticancer treatment. - In many studies, it has been reported that various types of circulating cell free DNA (CFD) are increased in various cancer types. - Recently, a fluorescence based CFD method that can directly measure nucleic acids without a DNA extraction process has been developed, which makes testing simpler and more economical, and can be conveniently applied to cancer diagnosis and treatment response. - This study is plan to evaluate the relationship between fluorescence-based CFD and treatment response in patients starting palliative chemotherapy, and check whether it can serve as a response evaluation for palliative chemotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Recruiting |
NCT05548933 -
Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia
|
||
| Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
| Recruiting |
NCT05372159 -
Vanderbilt Memory and Aging Project
|
||
| Completed |
NCT03173586 -
Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women
|
N/A | |
| Completed |
NCT04554628 -
Early Prediction of Acute Kidney Injury Among Patients Admitted to Surgical ICU
|
N/A | |
| Terminated |
NCT03250312 -
The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers
|
N/A | |
| Recruiting |
NCT04666766 -
Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers
|
N/A | |
| Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
| Completed |
NCT03193671 -
Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis
|
N/A | |
| Recruiting |
NCT06047132 -
PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS
|
||
| Completed |
NCT05361460 -
Patients Experiences of Early Postoperative Cognition
|
||
| Recruiting |
NCT05706194 -
Early Neuroprognostication After OHCA
|
||
| Recruiting |
NCT05138731 -
Metabolomics Profiling of Coronary Heart Disease
|
||
| Not yet recruiting |
NCT04563000 -
Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest
|
Phase 2 | |
| Completed |
NCT05138692 -
Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
|
||
| Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
| Active, not recruiting |
NCT02732301 -
Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers
|
||
| Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A | |
| Recruiting |
NCT04062279 -
Predictors of Parkinson's Disease Progression
|